Articles from Etiometry

Etiometry, the leader in clinical decision support software for high-acuity units, celebrates a year of groundbreaking achievements in 2024 and shares its ambitious vision to transform critical care in the year ahead. In 2024, the company achieved significant milestones across scalability, innovation and clinical impact, thereby solidifying its role as an effective tool to drive better patient outcomes and improved economics within the most complex and expensive hospital units.

Etiometry, the pioneer and leader in AI-based clinical decision-support software for high-acuity units, announces the commercial release of its Algorithm Development Kit (ADK) 2.0, designed specifically for clinician researchers aiming to develop, validate, and deploy advanced clinical algorithms for the ICU. With the Etiometry ADK 2.0, researchers now have access to the very tools and infrastructure used by Etiometry to secure nine FDA clearances—bringing unparalleled regulatory rigor and scalability to their own research and algorithm development.

Etiometry, the pioneer and leader in AI-based clinical decision-support software for high-acuity units, continues to transform ICU care through its Clinical Pathway Automation, which enables care teams to standardize workflows in line with their hospital guidelines and thereby enhance patient outcomes and drive cost savings. In the third quarter of 2024, Etiometry accelerated deployment of Clinical Pathway Automation with pathways now present in all ICU segments (e.g., adult, cardiac, neuro, pediatric) – within top U.S. medical centers. Etiometry has plans to launch more pathways by the end of 2024 to address the growing demand and each unit type’s unique requirements.

Etiometry, the leader in clinical decision-support software for critical care, today announced three new enterprise hospital agreements, further expanding its presence in adult and pediatric ICUs. These deals bring Etiometry's AI-based clinical intelligence platform to a major healthcare system in a large Midwestern city and renowned healthcare providers in Illinois and Utah - representing a significant addition to Etiometry's ever-growing customer base and presence across the critical care market.

Radiometer, a leading medical device company specializing in acute care testing solutions, and Etiometry, a leader in clinical decision-support software for critical care, today announced a new commercial partnership to enhance clinical decision making and workflows in hospital settings. Integrating the Etiometry platform with Radiometer’s acute care diagnostic solutions, empowers clinicians in critical care settings to view blood gas results, along with other physiologic parameters, other key clinical data, and AI-based patient risk analytics consolidated on a single screen.

Etiometry, the leader in clinical decision-support software for critical care, today shared 2024 priorities as well as highlights from 2023, which marked a momentous year for the company’s platform advancements, including deeper EHR enhancements and waveforms; additional FDA clearances for AI-based algorithms, and – most notably – clinical outcomes data that show platform use reduces length of stay (LOS), among other significant findings.

Etiometry, the leader in clinical decision-support software, shares exciting new study results from ten hospitals, including Boston Children’s Hospital, Children’s of Alabama, Children’s National Hospital and St. Louis Children’s Hospital, that demonstrate the significant impact its platform has on outcomes for critically ill patients. Physician researchers presented their findings at the World Congress of Pediatric Cardiology and Cardiac Surgery (WCPCCS) in Washington, D.C. on Monday, Aug. 28, 2023.

Etiometry, the leader in clinical decision-support software for high-acuity care teams, has successfully completed its Systems and Organizational Control (SOC) 2 Type 2 examination. As one of the most stringent, industry-accepted compliance frameworks, SOC 2 standards underscore Etiometry’s commitment to security, confidentiality and data integrity, as the company aims to support hospital customers seeking to employ cloud technology.

Etiometry, the leader in clinical decision-support software, announced today its IVCO2 Index™ was cleared by the Food and Drug Administration for use with neonatal ICU patients under 2kg, who are especially vulnerable to the effects of hypercapnia. This is Etiometry’s 9th FDA clearance and its second this year.

Etiometry, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 Index™ for adult populations, which allows clinicians to visualize inadequate ventilation of carbon dioxide with other contextual data from the Etiometry Platform to help inform intervention decisions and get ahead of patient deterioration. The IVCO2 Index was first FDA-cleared for pediatric use in 2019 and now carries CE Mark and Health Canada licenses for both pediatric and adult use.

Etiometry, the leader in clinical decision-support software for critical care, today provided a glimpse into its 2023 priorities as well as highlights from 2022, which marked a landmark year of growth for the company – including its database volume, which now exceeds 150 million hours of deidentified data signals. These patient-generated data are key to scaling Etiometry’s technology to serve additional populations and inform the company’s risk algorithms, which bolster the platform’s use as a safety net for clinicians caring for critically ill patients.

Etiometry, a leader in clinical decision-support software, announced today its IDO2 Index™ was cleared for adult use by the Food and Drug Administration. Now, U.S. hospitals can arm adult critical care teams with risk analytics that alert them to patients likely experiencing inadequate oxygen delivery. With this heightened situational awareness, clinicians can take action to avoid complications related to hypoxic conditions – a fundamental mission in critical care medicine. The IDO2 Index™ is Etiometry’s first FDA-cleared index for adults in the U.S. and follows Health Canada and CE Mark approvals for pediatric and adult patients in 2022.

Etiometry, a leader in clinical decision-support software for critical care, announced today that the company has obtained the CE Mark under the European Union's medical device regulation, marking the second adult and third pediatric market authorization. Etiometry's AI-powered clinical decision tool helps clinicians identify subtle signs of deterioration and enable effective care coordination, with published evidence demonstrating decreased length of stay and readmissions.

Etiometry, a leader in clinical decision-support software for critical care, announced today that it has doubled its FDA-cleared risk analytics portfolio to four indices, further strengthening its capability to track the fundamental pathways through which patients deteriorate under intensive care. Etiometry is the only critical care AI decision-support company with four FDA-cleared algorithms. The platform’s seven total FDA clearances demonstrate the scalability of its patented Risk Analytics Technology and its expanding ability to transform continuously acquired physiologic data into essential insights for clinical decision-making.

Etiometry, a leader in clinical decision-support software for critical care, and Radiometer, a leading medical device company specializing in acute care testing solutions, today announced a new collaboration to enhance the clinical workflows in Neonatal Intensive Care Units (NICU).

Etiometry, a leader in clinical decision-support software for the intensive care environment, today, announced substantial business growth and expansion in 2021. The successful year for Etiometry included achieving new sales milestones, inking a key strategic collaboration, expanding into new patient populations and clinical institutions, conducting meaningful research, and securing new funding. With the accomplishments of 2021, Etiometry is poised to continue its strong trajectory in 2022.

Etiometry, a leader in clinical decision-support software for critical care, today jointly announced a new collaboration with Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and a subsidiary of Japan-based Terumo Corporation (TSE: 4543). The partnership will bring advanced clinical decision support to adult cardiac surgery patients during surgery and their post-surgery recovery. Etiometry’s platform helps clinicians better manage patient data and provides actionable information in intensive care settings. Pairing this solution with Terumo’s cardiac surgical devices will bring deeper understanding and enhanced perioperative management of a patient’s condition.

Etiometry, a leader in clinical decision-support software for the intensive care environment, today announced a fully subscribed $9 million Series A-3 extension raise to fund commercial expansion, accelerate vital research and development, support leadership team expansion, and drive clinical initiatives. This latest round of funding was led by SKK 9i Ventures, with participation from Shamrock Holdings and other healthcare investors. The additional capital comes after significant growth and expansion in 2020 and will be used to help extend use of the company’s software to other hospital care settings.